In summary, we developed a precursor and a unique synthetic procedure for the highly economic production of [18F]PSMA-1007 injection solution, [18F]PSMA-1007 being the next generation 18F-tracer for the diagnosis and noninvasive staging of PSMA-positive prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.